m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG04115)
Name
PF-04523655
Status
Phase 2
TTD Drug ID
D01VVL
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
HIF-1 responsive protein RTP801 (DDIT4)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary HIF-1 responsive protein RTP801 (DDIT4) is a therapeutic target for PF-04523655. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PF-04523655 through regulating the expression of HIF-1 responsive protein RTP801 (DDIT4). [1], [2]
References
Ref 1 m(6)A mRNA methylation-directed myeloid cell activation controls progression of NAFLD and obesity. Cell Rep. 2021 Nov 9;37(6):109968. doi: 10.1016/j.celrep.2021.109968.
Ref 2 Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev. 2004 Apr 1;18(7):830-50. doi: 10.1101/gad.1200704.